Phase 2 data suggests retatrutide may produce greater weight reduction than currently approved agents, but its long-term safety profile has not been fully established, and no head-to-head regulatory-grade trials have been completed
The pigment persistences were linear, some central, others peripheral and finally punctual in the same sites, which required the vaporization to be deepened increasingly in a fractional manner
Patients transferring from another weight-loss prescription program, even from a different telehealth platform or physician, may qualify with a BMI of 22 or higher
Losing muscle can make blood sugar harder to control and worsen insulin resistance
Generally speaking, a baseline cost is around $495, plus an additional amount for longer dosing schedules
extended use requires monitoring